Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease
Introduction
In industrialised countries coronary artery disease (CAD) is the major cause of death in women. The mortality rate from CAD is about 3–4 fold that related to cancer. The risk of developing atherothrombotic CAD is associated with various factors. Modulation of these factors is a potential tool for the primary and secondary prevention of CAD, and may therefore be of great importance for the cardiovascular health in the individual, but it may also have a substantial socio-economic impact.
In women as compared to men, the incidence of CAD is low before the age of 50. In contrast, in women older than 50, CAD risk strongly increases, indicating that the postmenopausal oestrogen deficiency state is a major risk factor in the development of CAD. Moreover, young ovariectomised women also suffer from an increased risk of dying from CAD [1], which supports the hypothesis that loss of ovarian function increases CAD risk.
Accumulating evidence supports the suggested cardiovascular protective role of postmenopausal hormone replacement therapy (HRT) 2, 3. Many epidemiological studies and several meta-analyses have reported a 50% lower incidence of CAD in oestrogen users compared with non-users [4], and comparable data have recently been published for combined oestrogen–progestogen users [5]. In addition, experimental studies in monkeys [6], in rabbits and rats have demonstrated that hormone administration reduces the arterial cholesterol accumulation.
The cardiovascular protective influence of HRT appears to be of special benefit in women at high risk for CAD 7, 8, 9, 10, 11, 12. In the Lipid Research Clinic study, Bush et al. [7]reported a stronger reduction in CAD mortality in oestrogen-using hyperlipidaemic women compared with oestrogen-using normo-lipidaemic women. Ross et al. [8]demonstrated, in oestrogen-using women, that CAD mortality was relatively more reduced in heavy smokers when compared with non-smoking women. Ten-year mortality in oestrogen-using versus non-using women with angiographically proven CAD was more reduced in women with severe coronary stenosis than in women with normal angiography [9].
Section snippets
Risk factors
An increasing number of factors have been identified which influence the risk of developing CAD. For many years, most attention was given to the impact on CAD risk due to changes in serum lipids and lipoproteins, and it was demonstrated that postmenopausal women have a more atherogenic lipid profile when compared with premenopausal women. Furthermore, HRT was found to have favourable effects on the lipid profile reflected by a reduction in the atherogenic LDL-cholesterol and an increase in the
Blood pressure
The effects of HRT on blood pressure have scarcely been investigated. Most studies have reported no change or a small decrease in systolic and diastolic blood pressures 13, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91. Proposed mechanisms to explain these observations are vasodilation [92], possibly related to calcium antagonistic effects of oestrogens [93], and inhibition of the angiotensin-converting-enzyme [94].
Conclusions
Based on the literature presently available, there is strong evidence that cholesterol, Lp(a) and homocysteine, as important predictors for occlusive arterial disease, can be favourably modulated by HRT, and that the strongest reductions can be achieved in women with the highest concentrations.
Although clinical trials still need to demonstrate the impact of lowering concentrations of homocysteine and Lp(a), HRT appears to be a promising risk reduction strategy in this respect.
References (94)
- et al.
Hormone replacement and the menopause: a European position paper
Eur J Obstet Gynecol Reprod Biol
(1997) - et al.
Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations
Eur J Obstet Gynecol Reprod Biol
(1997) - et al.
The epidemiology of coronary heart disease and estrogen replacement in postmenoausal women
Prog Cardiol Dis
(1995) - et al.
Estrogen replacement therapy after coronary angioplasty in women
J Am Coll Cardiol
(1997) - et al.
Beneficial effect of estrogen on exercise-induced myocardial ischaemia in women with coronary artery disease
Lancet
(1993) - et al.
Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review
Maturitas
(1990) Effects of continuous combined hormone-replacement therapy on lipid levels in hypercholesterolemic postmenopausal women
Am J Med
(1995)- et al.
Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy
Obstet Gynecol
(1996) - et al.
Effect of oestrogen and progestin on plasma Lp(a) levels in postmenopausal women
Lancet
(1991) - et al.
Hormonal agents used in lowering lipoprotein(a)
Chem Phys Lipids
(1994)
Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, excercise, and estrogen
Am J Obstet Gynecol
A 2-year study on the beneficial effects of 17β-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone
Eur J Obstet Gynecol Reprod Biol
Lipoprotein(a) levels are reduced by danazol, an anabolic steroid
Atherosclerosis
Plasma homocysteine and cardiovascular disease mortality
Lancet
The effects of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women
Fertil Steril
Postmenopausal oral 17β-oestradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels
Fertil Steril
A randomized controlled study of the effects of 17β-oestradiol-dydrogesterone on plasma homocysteine in postmenopausal women
Obstet Gynecol
Exercise echocardiography in postmenopausal hormone users with mild systemic hypertension
Am J Cardiol
Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy
Obstet Gynecol
Cardiovascular protection by oestrogen—a calcium antagonist effect?
Lancet
Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women
Lancet
Menopause and heart disease: a review
Ann NY Acad Sci
Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
New Engl J Med
Regression of atherosclerosis in female monkeys
Arterioscler Thromb Vasc Biol
Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study
Circulation
Menopausal oestrogen therapy and protection from death from ischaemic heart disease
Lancet
Estrogen replacement and coronary artery disease: effects on survival in postmenopausal women
Arch Intern Med
Estrogen replacement therapy and prognosis after first myocardial infarction
Am J Epidemiol
Effects of estrogen/progestin regimen in heart disease risk factors in postmenopausal women
J Am Med Assoc
The effects of oestrogens on vessel wall and cardiac function, haemostasis and homocysteine metabolism
Eur Menopause J
The cardiovascular risk profile: influence of menopausal status and postmenopausal HRT
Gynaecology Forum
Short-term oestrogen replacement therapy improves resistance, lipids and fibrinolysis in postmenopausal women with NIDDM
Diabetologica
Effect of 17β-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus
Arterioscler Thromb Vasc Biol
Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women
J Clin Endocrinol Metab
Lipid profiles in estrogen users
Transdermal oestradiol plus medroxyprogesteron acetate lowers cholesterol in moderately hypercholesterolemic women
Maturitas
Natural oestrogen as an effective treatment for type-II hyperlipoproteinaemia in postmenopausal women
Lancet
Effects of transdermal 17β-oestradiol combined with oral progestogen on lipids and lipoproteins in hypercholesterolaemic postmenopausal women
J Int Med
Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
New Engl J Med
A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women
Arch Int Med
Lipoprotein(a): a risk factor for myocardial infarction
Arteriosclerosis
Lipoprotein(a) and atherosclerosis
Ann Intern Med
Lipoprotein(a) and coronary heart disease
Curr Opin Lipidol
Diet and drug therapy for lipoprotein(a)
Curr Opin Lipidol
Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population
Clin Chem
Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy
Arch Intern Med
Cited by (37)
17β-estradiol potentiates endothelium-dependent nitric oxide- and hyperpolarization-mediated relaxations in blood vessels of male but not female apolipoprotein-E deficient mice
2015, Vascular PharmacologyCitation Excerpt :One explanation for these observations is that female sex hormones exert a protective role on the vasculature. Indeed, 17β-estradiol (the major isoform of estrogen), reduces the development of atherosclerotic plaques [4–7], partly by inhibiting lipoprotein oxidation [8] and partly by modulating nitric oxide (NO) signaling [9–11]. Estrogens affect the latter through both genomic and non-genomic mechanisms.
Hormone Replacement Therapy: Looking Closely at Low Dose
2004, Principles of Gender-Specific MedicineA comparison of the effects of sequential transdermal versus continuous orally administered hormone replacement therapies on plasma total homocysteine levels in postmenopausal women: A randomized, placebo-controlled study
2007, European Journal of Obstetrics and Gynecology and Reproductive BiologyCitation Excerpt :Furthermore, it has been suggested that elevated total Hcy levels have a direct effect on the endothelium by increasing vascular uptake of LDL-C [3,4]. It has also been demonstrated that menopausal status is a associated causative factor resulting in a significant increase in plasma Hcy levels and leading to an increase in cardiovascular disease among women [6,8–10,14]. In parallel, levels of serum Hcy after both fasting and methionine loading are found to be higher in postmenopausal women than in premenopausal women [12,13].
Effect of hormone replacement therapy and tibolone on serum total homocysteine levels in postmenopausal women
2004, European Journal of Obstetrics and Gynecology and Reproductive Biology